Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Molecular Cancer
Published in: Molecular Cancer 1/2003

Open Access 01-12-2003 | Review

Apoptosis: Targets in Pancreatic Cancer

Authors: Sabine Westphal, Holger Kalthoff

Published in: Molecular Cancer | Issue 1/2003

Login to get access

Abstract

Pancreatic adenocarcinoma is characterized by poor prognosis, because of late diagnosis and lack of response to chemo- and/or radiation therapies. Resistance to apoptosis mainly causes this insensitivity to conventional therapies. Apoptosis or programmed cell death is a central regulator of tissue homeostasis. Certain genetic disturbances of apoptotic signaling pathways have been found in carcinomas leading to tumor development and progression. In the past few years, the knowledge about the complex pathways of apoptosis has strongly increased and new therapeutic approaches based on this knowledge are being developed. This review will focus on the role of apoptotic proteins contributing to pancreatic cancer development and progression and will demonstrate possible targets to influence this deadly disease.
Appendix
Available only for authorised users
Literature
1.
2.
Coppola D: Molecular prognostic markers in pancreatic cancer. Cancer Contr. 2000, 7: 421-427.
3.
von Bernstorff W, Spanjaard RA, Chan AK, Lockhart DC, Sadanaga N, Wood I, Peiper M, Goedegebuure PS, Eberlein TJ: Pancreatic cancer cells can evade immune surveillance via nonfunctional Fas (APO-1/CD95) receptors and aberrant expression of functional Fas ligand. Surgery. 1999, 125: 73-84.PubMedCrossRef
4.
Beger HG, Büchler MW, Friess H: Surgical results and indications for adjuvant measures in pancreatic cancer. Chirurg. 1994, 65: 246-252.PubMed
5.
Guo X, Friess H, Graber HU, Kashiwagi M, Zimmermann A, Korc M, Büchler MW: KAI1 expression is up-regulated in early pancreatic cancer and decreased in the presence of metastases. Cancer Res. 1996, 56: 4876-4880.PubMed
6.
Friess H, Büchler M, Krüger M, Beger HG: Treatment of duct carcinoma of the pancreas with the LH-RH-analogue buserelin. Pancreas. 1992, 7: 516-521.PubMedCrossRef
7.
Andren-Sandberg A, Bäckman PL, Andersson R: Results of adjuvant therapy in resected pancreatic cancer. Int J Pancreatol. 1997, 21: 31-38.PubMed
8.
Palmer KR, Kerr M, Knowles G, Cull A, Carter DC, Leonard RC: Chemotherapy prolongs survival in inoperable pancreatic carcinoma. Br J Surg. 1994, 81: 882-885.PubMedCrossRef
9.
von Bernstorff W, Voss M, Freichel S, Schmid A, Vogel I, Johnk C, Henne-Bruns D, Kremer B, Kalthoff H: Systemic and local immunosuppression in pancreatic cancer patients. Clin Cancer Res. 2001, 7: 925s-932s.PubMed
10.
Ungefroren H, Voss M, Jansen M, Roeder C, Henne-Bruns D, Kremer B, Kalthoff H: Human pancreatic adenocarcinomas express Fas and Fas ligand yet are resistant to Fas-mediated apoptosis. Cancer Res. 1998, 58: 1741-1749.PubMed
11.
Igney FH, Krammer PH: Death and anti-death: Tumour resistance to apoptosis. Nature Rev Cancer. 2002, 2: 277-288.CrossRef
12.
Miyashita T, Reed JC: Bcl-2 oncoprotein blocks chemotherapy-induced apoptosis in a human leukemia cell line. Blood. 1993, 81: 151-157.PubMed
13.
Korsmeyer SJ: Bcl-2 initiates a new category of oncogenes: regulators of cell death. Blood. 1992, 80: 879-886.PubMed
14.
Hager JH, Hanahan D: Tumor cells utilize multiple pathways to down-modulate apoptosis. Lessons from a mouse model of islet cell carcinogenesis. Ann N Y Acad Sci. 1999, 887: 150-163.PubMedCrossRef
15.
Itoh N, Yonehara S, Ishii A, Yonehara M, Mizushima S, Sameshima M, Hase A, Seto Y, Nagata S: The polypeptide encoded by the cDNA for human cell surface antigen Fas can mediate apoptosis. Cell. 1991, 66: 233-243.PubMedCrossRef
16.
Suda T, Takahashi T, Golstein P, Nagata S: Molecular cloning and expression of the Fas ligand, a novel member of the tumor necrosis factor family. Cell. 1993, 75: 1169-1178.PubMedCrossRef
17.
Krammer PH, Galle PR, Moller P, Debatin KM: CD95 (APO-1/Fas)-mediated apoptosis in normal and malignant liver, colon, and hematopoietic cells. Adv Cancer Res. 1998, 75: 251-273.PubMedCrossRef
18.
Sprick MR, Weigand MA, Rieser E, Rauch CT, Juo P, Blenis J, Krammer PH, Walczak H: FADD/MORT1 and caspase-8 are recruited to TRAIL receptors 1 and 2 and are essential for apoptosis mediated by TRAIL receptor 2. Immunity. 2000, 12: 599-609.PubMedCrossRef
19.
Scaffidi C, Fulda S, Srinivasan A, Friesen C, Li F, Tomaselli KJ, Debatin KM, Krammer PH, Peter ME: Two CD95 (APO-1/Fas) signaling pathways. EMBO J. 1998, 17: 1675-1687.PubMedCentralPubMedCrossRef
20.
Zamzami N, Kroemer G: The mitochondrion in apoptosis: how Pandora's box opens. Nature Rev Mol Cell Biol. 2001, 2: 67-71.CrossRef
21.
Martinou JC, Green DR: Breaking the mitochondrial barrier. Nature Rev Mol Cell Biol. 2001, 2: 63-67.CrossRef
22.
Rathmell JC, Thompson CB: The central effectors of cell death in the immune system. Annu Rev Immunol. 1999, 17: 781-828.PubMedCrossRef
23.
24.
Wyllie AH: Apoptosis and carcinogenesis. Eur J Cell Biol. 1997, 73: 189-197.PubMed
25.
26.
Niehans GA, Brunner T, Frizelle SP, Liston JC, Salerno CT, Knapp DJ, Green DR, Kratzke RA: Human lung carcinomas express Fas ligand. Cancer Res. 1997, 57: 1007-1012.PubMed
27.
Horie S, Kano M, Higashihara E, Moriyama N, Tanaka E, Hirose A, Kakizoe T, Kawabe K: Expression of Fas in renal cell carcinoma. Jpn J Clin Oncol. 1997, 27: 384-388.PubMedCrossRef
28.
von Reyher U, Strater J, Kittstein W, Gschwendt M, Krammer PH, Moller P: Colon carcinoma cells use different mechanisms to escape CD95-mediated apoptosis. Cancer Res. 1998, 58: 526-534.PubMed
29.
30.
von Bernstorff W, Glickman JN, Odze RD, Farraye FA, Joo HG, Goedegebuure PS, Eberlein TJ: Fas (CD95/APO-1) and Fas ligand expression in normal pancreas and pancreatic tumors. Implications for immune privilege and immune escape. Cancer. 2002, 94: 2552-2560.CrossRef
31.
Snell V, Clodi K, Zhao S, Goodwin R, Thomas EK, Morris SW, Kadin ME, Cabanillas F, Andreeff M, Younes A: Activity of TNF-related apoptosis-inducing ligand (TRAIL) in haematological malignancies. Br J Haematol. 1997, 99: 618-624.PubMedCrossRef
32.
Hinz S, Trauzold A, Boenicke L, Sandberg C, Beckmann S, Bayer E, Walczak H, Kalthoff H, Ungefroren H: Bcl-xL protects pancreatic adenocarcinoma cells against CD95- and TRAIL-receptor-mediated apoptosis. Oncogene. 2000, 19: 5477-5486.PubMedCrossRef
33.
Matsuzaki H, Schmied BM, Ulrich A, Standop J, Schneider MB, Batra SK, Picha KS, Pour PM: Combination of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) and actinomycin D induces apoptosis even in TRAIL-resistant human pancreatic cancer cells. Clin Cancer Res. 2001, 7: 407-414.PubMed
34.
Ashkenazi A, Pai RC, Fong S, Leung S, Lawrence DA, Marsters SA, Blackie C, Chang L, McMurtrey AE, Hebert A, DeForge L, Koumenis IL, Lewis D, Harris L, Bussiere J, Koeppen H, Shahrokh Z, Schwall RH: Safety and antitumor activity of recombinant soluble Apo2 ligand. J Clin Invest. 1999, 104: 155-162.PubMedCentralPubMedCrossRef
35.
Jo M, Kim TH, Seol DW, Esplen JE, Dorko K, Biliar TR, Strom SC: Apoptosis induced in normal human hepatocytes by tumor necrosis factor-related apoptosis-inducing ligand. Nat Med. 2000, 6: 564-567.PubMedCrossRef
36.
Sato T, Irie S, Kitada S, Reed JC: FAP-1: a protein tyrosine phosphatase that associates with Fas. Science. 1995, 268: 411-415.PubMedCrossRef
37.
Ungefroren H, Kruse ML, Trauzold A, Roeschmann S, Roeder C, Arlt A, Henne-Bruns D, Kalthoff H: FAP-1 in pancreatic cancer cells: functional and mechanistic studies on its inhibitory role in CD95-mediated apoptosis. J Cell Sci. 2001, 114: 2735-2746.PubMed
38.
Trauzold A, Wermann H, Arlt A, Schütze S, Schäfer H, Oestern S, Roeder C, Ungefroren H, Lampe E, Heinrich M, Walczak H, Kalthoff H: CD95 and TRAIL receptor-mediated activation of protein kinase C and NF-κB contributes to apoptosis resistance in ductal pancreatic adenocarcinoma cells. Oncogene. 2001, 20: 4258-4269.PubMedCrossRef
39.
Adams JM, Cory S: The Bcl-2 protein family: Arbiter of cell survival. Science. 1998, 281: 1322-1326.PubMedCrossRef
40.
Kelekar A, Thompson CB: Bcl-2 family proteins: the role of the BH3 domain in apoptosis. Trends Cell Biol. 1998, 8: 324-330.PubMedCrossRef
41.
42.
Gutierrez-Puente Y, Zapata-Benavides P, Tari AM, Lopez-Berestein G: Bcl-2 related antisense therapy. Semin Oncol. 2002, 29: 71-76.PubMed
43.
Evans JD, Cornford PA, Dodson A, Greenhalf W, Foster CS, Neoptolemos JP: Detailed tissue expression of bcl-2, bax, bak and bcl-x in the normal human pancreas and in chronic pancreatitis, ampullary and pancreatic ductal adenocarcinomas. Pancreatology. 2001, 1: 254-262.PubMedCrossRef
44.
Campani D, Esposito I, Boggi U, Cecchetti D, Menicagli M, De Negri F, Colizzi L, Del Chiaro M, Mosca F, Fornaciari G, Bevilacqua G: Bcl-2 expression in pancreas development and pancreatic cancer progression. J Pathol. 2001, 194: 444-450.PubMedCrossRef
45.
Dias N, Stein CA: Potential roles of antisense oligonucleotides in cancer therapy. The example of Bcl-2 antisense oligonucleotides. Eur J Pharm Biopharm. 2002, 54: 263-269.PubMedCrossRef
46.
Ehlert JE, Kubbutat MH: Apoptosis and its relevance in cancer therapy. Onkologie. 2001, 24: 433-440.PubMedCrossRef
47.
Tsujimoto Y: Role of Bcl-2 family proteins in apoptosis: apoptosomes or mitochondria?. Genes Cells. 1998, 3: 697-707.PubMedCrossRef
48.
Hu Y, Benedict MA, Wu D, Inohara N, Nùnez G: Bcl-xL interacts with Apaf-1 and inhibits Apaf-1-dependent caspase-9 activation. Proc Natl Acad Sci U S A. 1998, 95: 4386-4391.PubMedCentralPubMedCrossRef
49.
Xu Z, Friess H, Solioz M, Aebi S, Korc M, Kleeff J, Büchler MW: Bcl-x(L) antisense oligonucleotides induce apoptosis and increase sensitivity of pancreatic cancer cells to gemcitabine. Int J Cancer. 2001, 94: 268-274.PubMedCrossRef
50.
Shi X, Liu S, Kleeff J, Friess H, Büchler MW: Acquired resistance of pancreatic cancer cells towards 5-Fluorouracil and gemcitabine is associated with altered expression of apoptosis-regulating genes. Oncology. 2002, 62: 354-362.PubMedCrossRef
51.
Friess H, Lu Z, Andrén-Sandberg A, Berberat P, Zimmermann A, Adler G, Schmid R, Büchler MW: Moderate activation of the apoptosis inhibitor Bcl-xL worsens the prognosis in pancreatic cancer. Ann Surg. 1998, 228: 780-787.PubMedCentralPubMedCrossRef
52.
53.
Finucane DM, Bossy-Wetzel E, Waterhouse NJ, Cotter TG, Green DR: Bax-induced caspase activation and apoptosis via cytochrome c release from mitochondria is inhibitable by Bcl-xL. J Biol Chem. 1999, 274: 2225-2233.PubMedCrossRef
54.
Xu ZW, Friess H, Büchler MW, Solioz M: Overexpression of Bax sensitizes human pancreatic cancer cells to apoptosis induced by chemotherapeutic agents. Cancer Chemother Pharmacol. 2002, 49: 504-510.PubMedCrossRef
55.
Pirocanac EC, Nassirpour R, Yang M, Wang J, Nardin SR, Gu J, Fang B, Moossa AR, Hoffmann RM, Bouvet M: Bax-induction gene therapy of pancreatic cancer. J Surg Res. 2002, 106: 346-351.PubMedCrossRef
56.
Seki T, Ohba N, Makino R, Funatomi H, Mitamura K: Mechanism of growth-inhibitory effect of cisplatin on human pancreatic cancer cells and status of p53 gene. Anticancer Res. 2001, 21: 1919-1924.PubMed
57.
Graber HU, Friess H, Zimmermann A, Korc M, Adler G, Schmid R, Büchler MW: Bak expression and cell death occur in peritumorous tissue but not in pancreatic cancer cells. J Gastrointest Surg. 1999, 3: 74-80.PubMedCrossRef
58.
Adachi M, Imai K: The proapoptotic BH3-only protein BAD transduces cell death signals independently of its interaction with Bcl-2. Cell Death and Differ. 2002, 9: 1240-1247.CrossRef
59.
Baell JB, Huang DC: Prospects for targeting the Bcl-2 family of proteins to develop novel cytotoxic drugs. Biochem Pharmacol. 2002, 64: 851-863.PubMedCrossRef
60.
Ding XZ, Tong WG, Adrian TE: Cyclooxygenases and lipoxygenases as potential targets for treatment of pancreatic cancer. Pancreatology. 2001, 1: 291-299.PubMedCrossRef
61.
Tong WG, Ding XZ, Adrian TE: The mechanisms of lipoxygenase inhibitor-induced apoptosis in human breast cancer cells. Biochem Biophys Res Commun. 2002, 296: 942-948.PubMedCrossRef
62.
Turk B, Stoka V, Rozman-Pungercar J, Cirman T, Droga-Mazovec G, Oreic K, Turk V: Apoptotic pathways: involvement of lysosomal proteases. Biol Chem. 2002, 383: 1035-1044.PubMed
63.
64.
Kothakota S, Azuma T, Reinhard C, Klippel A, Tang J, Chu K, McGarry TJ, Kirschner MW, Koths K, Kwiatkowski DJ, Williams LT: Caspase-3-generated fragment of gelsolin: effector of morphological change in apoptosis. Science. 1997, 278: 294-298.PubMedCrossRef
65.
Takahashi A, Alnemri ES, Lazebnik YA, Fernandes-Alnemri T, Litwack G, RD Moir, Goldman RD, Poirier GG, Kaufmann SH, Earnshaw WC: Cleavage of lamin A by Mch2α but not CPP32: Multiple interleukin 1-β converting enzyme-related proteases with distinct substrate recognition properties are active in apoptosis. Proc Natl Acad Sci U S A. 1996, 93: 8395-8400.PubMedCentralPubMedCrossRef
66.
67.
Boldin M, Goncharov TM, Goltsev YV, Wallach D: Involvement of MACH, a novel MORT1/FADD-interacting protease, in Fas/Apo-1-and TNF receptor-induced cell death. Cell. 1996, 85: 803-815.PubMedCrossRef
68.
Li P, Nijhawan D, Budihardjo I, Srinivasula SM, Ahmad M, Alnemri ES, Wang X: Cytochrome c and dATP-dependent formation of Apaf-1/caspase-9 complex initiates an apoptotic protease cascade. Cell. 1997, 91: 479-489.PubMedCrossRef
69.
Irmler M, Thome M, Hahne M, Schneider P, Hofmann K, Steiner V, Bodmer JL, Schroter M, Burns K, Mattmann C, Rimoldi D, French LE, Tschopp J: Inhibition of death receptor signals by cellular FLIP. Nature. 1997, 388: 190-195.PubMedCrossRef
70.
Krueger A, Baumann S, Krammer PH, Kirchhoff S: FLICE-inhibitory proteins: regulators of death receptor-mediated apoptosis. Mol Cell Biol. 2001, 21: 8247-8254.PubMedCentralPubMedCrossRef
71.
Goltsev YV, Kovalenko AV, Arnold E, Varfolomeev EE, Brodianskii VM, Wallach D: CASH, a novel caspase homologue with death effector domains. J Biol Chem. 1997, 272: 19641-4.PubMedCrossRef
72.
Han DK, Chaudhary PM, Wright ME, Friedmann C, Trask BJ, Riedel RT, Baskin DG, Schwartz SM, Hood L: MRIT, a novel death-effector domain-containing protein, interacts with caspases and Bcl-xL and initiates cell death. Proc Natl Acad Sci U S A. 1997, 94: 11333-8.PubMedCentralPubMedCrossRef
73.
Elnemr A, Ohta T, Yachie A, Kayahara M, Kitagawa H, Fujimura T, Ninomiya I, Fushida S, Nishimura GI, Shimizu K, Miwa K: Human pancreatic cancer cells disable function of Fas receptors at several levels in Fas signal transduction pathway. Int J Oncol. 2001, 18: 311-316.PubMed
74.
Kataoka T, Budd RC, Holler N, Thome M, Martinon F, Irmler M, Burns K, Hahne M, Kennedy N, Kovacsovics M, Tschopp J: The caspase-8 inhibitor FLIP promotes activation of NF-κB and Erk signaling pathways. Curr Biol. 2000, 10: 640-648.PubMedCrossRef
75.
Bharti AC, Aggarwal BB: Nuclear factor-κB and cancer: its role in prevention and therapy. Biochem Pharmacol. 2002, 64: 883-888.PubMedCrossRef
76.
Hyer ML, Sudarshan S, Kim Y, Reed JC, Dang JY, Schwartz JY, Norris JS: Downregulation of c-FLIP sensitizes DU145 prostate cancer cells to Fas-mediated apoptosis. Cancer Biol Ther. 2002, 1: 401-406.PubMedCrossRef
77.
Kim Y, Suh N, Sporn M, Reed JC: An inducible pathway for degradation of FLIP protein sensitizes tumor cells to TRAIL-induced apoptosis. J Biol Chem. 2002, 277: 22320-22329.PubMedCrossRef
78.
Vernejoul F, Faure P, Benali N, Calise D, Tiraby G, Pradayrol L, Susini C, Buscail L: Antitumor effect of in vivo somatostatin receptor subtype 2 gene transfer in primary and metastatic pancreas cancer models. Cancer Res. 2002, 62: 6124-6131.PubMed
79.
Chakrabarty S, Roy M, Hazra B, Bhattacharya RK: Induction of apoptosis in human cancer cell lines by diospyrin, a plant-derived bisnaphthoquinoid, and its synthetic derivates. Cancer Lett. 2002, 188: 85-93.PubMedCrossRef
80.
Wang W, Waters SJ, MacDonald JR, Roth C, Shentu S, Freeman J, VonHoff DD, Miller AR: Irofulven (6-hydroxymethylacylfulvene, MGI 114)-induced apoptosis in human pancreatic cancer cells is mediated by ERK and JNK kinases. Anticancer Res. 2002, 22: 559-564.PubMed
81.
Birnbaum MJ, Clem RJ, Miller LK: An apoptosis-inhibiting gene from a nuclear polyhedrosis virus encoding a polypeptide with Cys/His sequence motifs. J Virol. 1994, 68: 2521-2528.PubMedCentralPubMed
82.
Crook NE, Clem RJ, Miller LK: An apoptosis-inhibiting baculovirus gene with a zinc finger-like motif. J Virol. 1993, 67: 2168-2174.PubMedCentralPubMed
83.
84.
Harvey AJ, Soliman H, Kaiser W, Miller LK: Anti- and pro-apoptotic activities of baculovirus and Drosophila IAPs in an insect cell line. Cell Death Differ. 1997, 4: 733-744.PubMedCrossRef
85.
Deveraux QL, Takahashi R, Salvesen GS, Reed JC: X-linked IAP is a direct inhibitor of cell death proteases. Nature. 1997, 388: 300-303.PubMedCrossRef
86.
Takahashi R, Deveraux Q, Tamm I, Welsh K, Assa-Munt N, GS Salvesen, Reed JC: A single BIR domain of XIAP sufficient for inhibiting caspases. J Biol Chem. 1998, 273: 7787-7790.PubMedCrossRef
87.
Roy N, Mahadevan MS, McLean M, Shutler G, Yaraghi Z, Farahani R, Baird S, Besner-Johnson A, Lefebvre C, Kang X, Salih M, Aubry H, Tamai K, Guan X, Ioannou P, Crawford TO, de Jong PJ, Surh L, Ikeda J-E, Korneluk RG, MacKenzie A: The gene for neuronal apoptosis inhibitory protein is partially deleted in individuals with spinal muscular atrophy. Cell. 1995, 80: 167-178.PubMedCrossRef
88.
Ekedahl J, Joseph B, Grigoriev MY, Muller M, Magnusson C, Lewensohn R, Zhivotovsky B: Expression of inhibitor of apoptosis proteins in small- and non-small-cell lung carcinoma cells. Exp Cell Res. 2002, 279: 277-290.PubMedCrossRef
89.
Hofmann HS, Simm A, Hammer A, Silber RE, Bartling B: Expression of inhibitors of apoptosis (IAP) proteins in non-small cell lung cancer. J Cancer Res Clin Oncol. 2002, 128: 554-560.PubMedCrossRef
90.
Zhang J, Li Y, Shen B: Up-regulation of XIAP by M-CSF is associated with resistance of myeloid leukemia cells to apoptosis. Leukemia. 2002, 16: 2163-2165.PubMedCrossRef
91.
McEleny KR, Watson RW, Coffey RN, O'Neill AJ, Fitzpatrick JM: Inhibitors of apoptosis proteins in prostate cancer cell lines. Prostate. 2002, 51: 133-140.PubMedCrossRef
92.
Li F, Ambrosini G, Chu EY, Plescia J, Tognin S, Marchisio PC, Altieri DC: Control of apoptosis and mitotic spindle checkpoint by survivin. Nature. 1998, 396: 580-583.PubMedCrossRef
93.
Tamm I, Wang Y, Sausville E, Scudiero DA, Vigna N, Oltersdorf T, Reed JC: IAP-family protein survivin inhibits caspase activity and apoptosis induced by Fas (CD95), Bax, caspases, and anticancer drugs. Cancer Res. 1998, 58: 5315-5320.PubMed
94.
Ambrosini G, Adida C, Altieri DC: A novel anti-apoptosis gene, survivin, expressed in cancer and lymphoma. Nat Med. 1997, 3: 917-921.PubMedCrossRef
95.
Yamamoto T, Tanigawa N: The role of survivin as a new target of diagnosis and treatment in human cancer. Med Electron Microsc. 2001, 34: 207-212.PubMedCrossRef
96.
Adida C, Berrebi D, Peuchmaur M, Reyes-Mugica M, Altieri DC: Anti-apoptosis gene, survivin, and prognosis of neuroblastoma. Lancet. 1998, 351: 882-883.PubMedCrossRef
97.
Kawasaki H, Altieri DC, Lu CD, Toyoda M, Tenjo T, Tanigawa N: Inhibition of apoptosis by survivin predicts shorter survival rates in colorectal cancer. Cancer Res. 1998, 58: 5071-5074.PubMed
98.
Lu CD, Altieri DC, Tanigawa N: Expression of novel anti-apoptosis gene, survivin, correlated with tumor cell apoptosis and p53 accumulation in gastric carcinomas. Cancer Res. 1998, 58: 1808-1812.PubMed
99.
Satoh K, Kaneko K, Hirota M, Masamune A, Satoh A, Shimosegawa T: Expression of survivin is correlated with cancer cell apoptosis and is involved in the development of human pancreatic duct cell tumors. Cancer. 2001, 92: 271-278.PubMedCrossRef
100.
Verhagen AM, Ekert PG, Pakusch M, Silke J, Connolly LM, Reid GE, Moritz RL, Simpson RJ, Vaux DL: Identification of DIABLO, a mammalian protein that promotes apoptosis by binding to and antagonizing IAP proteins. Cell. 2000, 102: 43-53.PubMedCrossRef
101.
Du C, Fang M, Li Y, Li L, Wang X: Smac, a mitochondrial protein that promotes cytochrome c-dependent caspase activation by eliminating IAP inhibition. Cell. 2000, 102: 33-42.PubMedCrossRef
102.
Verhagen AM, Vaux DL: Cell death regulation by the mammalian IAP antagonist Diablo/Smac. Apoptosis. 2002, 7: 163-166.PubMedCrossRef
103.
Arnt CR, Chiorean MV, Heldebrant MP, Gores GJ, Kaufmann SH: Synthetic Smac/DIABLO peptides enhance the effects of chemotherapeutic agents by binding XIAP and cIAP in situ. J Biol Chem. 2002, 277: 44236-44243.PubMedCrossRef
104.
105.
Porter AC, Vaillancourt RR: Tyrosine kinase receptor-activated signal transduction pathways which lead to oncogenesis. Oncogene. 1998, 17: 1343-1352.PubMedCrossRef
106.
Korc M, Chandrasekar B, Yamanaka Y, Friess H, Buchier M, Beger HG: Overexpression of the epidermal growth factor receptor in human pancreatic cancer is associated with concomitant increases in the level of epidermal growth factor and transforming growth factor alpha. J Clin Invest. 1992, 90: 1352-1360.PubMedCentralPubMedCrossRef
107.
Chen J, Liu TH: Expression of EGF, TGF-alpha, EGFR and c-erbB2 genes and their gene products in human pancreatic carcinoma cell lines. Zentralbl Pathol. 1994, 140: 265-270.PubMed
108.
Freeman JW, Mattingly CA, Strodel WE: Increased tumorigenicity in human pancreatic cell line MIA PaCa-2 is associated with an aberrant regulation of an IGF-1 autocrine loop and lack of expression of the TGF-beta type RII receptor. J Cell Physiol. 1995, 165: 155-163.PubMedCrossRef
109.
Bergmann U, Funatomi H, Yokoyama M, Berger HG, Korc M: Insulin-like growth factor I overexpression in human pancreatic cancer: evidence for autocrine and paracrine roles. Cancer Res. 1995, 55: 2007-2011.PubMed
110.
Ishiwata T, Bergmann U, Kornmann M, Lopez M, Beger HG, Korc M: Altered expression of insulin-like growth factor II receptor in human pancreatic cancer. Pancreas. 1997, 15: 367-373.PubMedCrossRef
111.
Korc M: Role of growth factors in pancreatic cancer. Surg Oncol Clin N Am. 1998, 7: 25-41.PubMed
112.
Arii S, Mori A, Uchida S, Fujimoto K, Shimada Y, Imamura M: Implication of vascular endothelial growth factor in the development and metastasis of human cancers. Hum Cell. 1999, 12: 25-30.PubMed
113.
Kalthoff H, Roeder C, Gieseking J, Humburg I, Schmiegel W: Inverse regulation of human ERBB2 and epidermal growth factor receptors by tumor necrosis factor alpha. Proc Natl Acad Sci U S A. 1993, 90: 8972-8976.PubMedCentralPubMedCrossRef
114.
Kalthoff H, Roeder C, Brockhaus M, Thiele HG, Schmiegel W: Tumor necrosis factor (TNF) up-regulates the expression of p75 but not p55 TNF receptors, and both receptors mediate, independently of each other, up-regulation of transforming growth factor alpha and epidermal growth factor receptor mRNA. J Biol Chem. 1993, 268: 2762-2766.PubMed
115.
Schmiegel W, Roeder C, Schmielau J, Rodeck U, Kalthoff H: Tumor necrosis factor alpha induces the expression of transforming growth factor alpha and the epidermal growth factor receptor in human pancreatic cancer cells. Proc Natl Acad Sci U S A. 1993, 90: 863-867.PubMedCentralPubMedCrossRef
116.
Grothey A, Voigt W, Schober C, Muller T, Dempke W, Schmoll HJ: The role of insulin-like growth factor I and its receptor in cell growth, transformation, apoptosis, and chemoresistance in solid tumors. J Cancer Res Clin Oncol. 1999, 125: 166-173.PubMedCrossRef
117.
Prisco M, Romano G, Peruzzi F, Valentinis B, Baserga R: Insulin and IGF-I receptors signaling in protection from apoptosis. Horm Metab Res. 1999, 31: 80-89.PubMedCrossRef
118.
Yao Z, Okabayashi Y, Yutsudo Y, Kitamura T, Ogawa W, Kasuga M: Role of Akt in growth and survival of PANC-1 pancreatic cancer cells. Pancreas. 2002, 24: 42-46.PubMedCrossRef
119.
DeBosch BJ, Deo BK, Kumagai AK: Insulin-like growth factor-1 effects on bovine retinal endothelial cell glucose transport: role of MAP kinase. J Neurochem. 2002, 81: 728-734.PubMedCrossRef
120.
Nair PN, De Armond DT, Adamo ML, Strodel WE, Freeman JW: Aberrant expression and activation of insulin-like growth factor-1 receptor (IGF-1R) are mediated by an induction of IGF-1R promoter activity and stabilization of IGF-1R mRNA and contributes to growth factor independence and increased survival of the pancreatic cancer cell line MIA PaCa-2. Oncogene. 2001, 20: 8203-8214.PubMedCrossRef
121.
Mitsiades CS, Mitsiades N, Poulaki V, Schlossman R, Akiyama M, Chauhan D, Hideshima T, Treon SP, Munshi NC, Richardson PG, Anderson KC: Activation of NF-κB and upregulation of intracellular anti-apoptotic proteins via the IGF-1/Akt signaling in human multiple myeloma cells: therapeutic implications. Oncogene. 2002, 21: 5673-5683.PubMedCrossRef
122.
Lopez T, Hanahan D: Elevated levels of IGF-1 receptor convey invasive and metastatic capability in a mouse model of pancreatic islet tumorigenesis. Cancer Cell. 2002, 1: 339-353.PubMedCrossRef
123.
Ghaneh P, Kawesha A, Evans JD, Neoptolemos JP: Topics: Pancreatic cancer-new horizons in diagnosis and treatment: Molecular prognostic markers in pancreatic cancer. J Hepatobiliary Pancreat Surg. 2002, 9: 1-11.PubMedCrossRef
124.
Shi X, Friess H, Kleeff J, Ozawa F, Büchler MW: Pancreatic cancer: factors regulating tumor development, maintenance and metastasis. Pancreatology. 2001, 1: 517-524.PubMedCrossRef
125.
Buchsbaum DJ, Bonner JA, Grizzle WE, Stackhouse MA, Carpenter M, Hicklin DJ, Bohlen P, Raisch KP: Treatment of pancreatic cancer xenografts with Erbitux (IMC-C225) anti-EGFR antibody, gemcitabine, and radiation. Int J Radiat Oncol Biol Phys. 2002, 54: 1180-1193.PubMedCrossRef
126.
Verheul HM, Pinedo HM: The role of vascular endothelial growth factor (VEGF) in tumor angiogenesis and early clinical development of VEGF-receptor kinase inhibitors. Clin Breast Cancer. 2000, 1 (Suppl 1): S80-84.PubMedCrossRef
127.
Sipos B, Weber D, Ungefroren H, Kalthoff H, Zühlsdorff A, Luther C, Török V, Klöppel G: Vascular endothelial growth factor mediated angiogenic potential of pancreatic ductal carcinomas enhanced by hypoxia: An in vitro and in vivo study. Int J Cancer. 2002, 102: 592-600.PubMedCrossRef
128.
Takayama K, Ueno H, Nakanishi Y, Sakamoto T, Inoue K, Shimizu K, Oohashi H, Hara N: Suppression of tumor angiogenesis and growth by gene transfer of a soluble form of vascular endothelial growth factor receptor into a remote organ. Cancer Res. 2000, 60: 2169-2177.PubMed
129.
Ogawa T, Takayama K, Takakura N, Kitano S, Ueno H: Anti-tumor angiogenesis therapy using soluble receptors: enhanced inhibition of tumor growth when soluble fibroblast growth factor receptor-1 is used with soluble vascular endothelial growth factor receptor. Cancer Gene Ther. 2002, 9: 633-640.PubMedCrossRef
130.
131.
Webber EM, FitzGerald MJ, Brown PI, Bartlett MH, Fausto N: Transforming growth factor-alpha expression during liver regeneration after partial hepatectomy and toxic injury, and potential interactions between transforming growth factor-alpha and hepatocyte growth factor. Hepatology. 1993, 18: 1422-1431.PubMedCrossRef
132.
Greten FR, Wagner M, Weber CK, Zechner U, Adler G, Schmid RM: TGF alpha transgenic mice. A model of pancreatic cancer development. Pancreatology. 2001, 1: 363-368.PubMedCrossRef
133.
Kanda D, Takagi H, Toyoda M, Horiguchi N, Nakajima H, Otsuka T, Mori M: Transforming growth factor alpha protects against Fas-mediated liver apoptosis in mice. FEBS Lett. 2002, 519: 11-15.PubMedCrossRef
134.
Schuster N, Kreiglstein K: Mechanisms of TGF-β-mediated apoptosis. Cell Tissue Res. 2002, 307: 1-14.PubMedCrossRef
135.
Voss M, Wolff B, Savitskaia N, Ungefroren H, Deppert W, Schmiegel W, Kalthoff H, Naumann M: TGFbeta-induced growth inhibition involves cell cycle inhibitor p21 and pRb independent from p15 expression. Int J Oncol. 1999, 14: 93-101.PubMed
136.
Ashley DM, Kong FM, Bigner DD, Hale LP: Endogenous expression of transforming growth factor beta1 inhibits growth and tumorigenicity and enhances Fas-mediated apoptosis in a murine high-grade glioma model. Cancer Res. 1998, 58: 302-309.PubMed
137.
Tobin SW, Brown MK, Douville K, Payne DC, Eastman A, Arrick BA: Inhibition of transforming growth factor beta signaling in MCF-7 cells results in resistance to tumor necrosis factor alpha: the role for Bcl-2. Cell Growth Differ. 2001, 12: 109-117.PubMed
138.
Shima Y, Nakao K, Nakashima T, Kawakami A, Nakata K, Hamasaki K, Kato Y, Eguchi K, Ishii N: Activation of caspase-8 in transforming growth factor-beta-induced apoptosis of human hepatoma cells. Hepatology. 1999, 30: 1215-1222.PubMedCrossRef
139.
Foghi A, Teerds KJ, van der Donk H, Moore NC, Dorrington J: Induction of apoptosis in thecal/interstitial cells: action of transforming growth factor (TGF) alpha plus TGF beta on bcl-2 and interleukin-1 beta-converting enzyme. J Endocrinol. 1998, 157: 489-494.PubMedCrossRef
140.
Arsura M, Wu M, Sonenshein GE: TGF beta 1 inhibits NF-κB/Rel activity inducing apoptosis of B cells: transcriptional activation of I kappa B alpha. Immunity. 1996, 5: 31-40.PubMedCrossRef
141.
Dijke PT, Goumans M-J, Itoh F, Itoh S: Regulation of cell proliferation by Smad proteins. J Cell Phys. 2002, 191: 1-16.CrossRef
142.
Antonello D, Moore PS, Zamboni G, Falconi M, Scarpa A: Absence of mutations in the transforming growth factor-beta inducible early gene 1, TIEG1, in pancreatic cancer. Cancer Lett. 2002, 183: 179-183.PubMedCrossRef
143.
Maurice D, Pierreux CE, Howell M, Wilentz RE, Owen MJ, Hill CS: Loss of Smad4 function in pancreatic tumors: C-terminal truncation leads to decreased stability. J Biol Chem. 2001, 276: 43175-43181.PubMedCrossRef
144.
Tascilar M, Skinner HG, Rosty C, Sohn T, Wilentz RE, Offerhaus GJ, Adsay V, Abrams RA, Cameron JL, Kern SE, Yeo CJ, Hruban RH, Goggins M: The SMAD4 protein and prognosis of pancreatic ductal adenocarcinoma. Clin Cancer Res. 2001, 7: 4115-4121.PubMed
145.
Beg AA, Baltimore D: An essential role for NF-κB in preventing TNF-α-induced cell death. Science. 1996, 274: 782-784.PubMedCrossRef
146.
Karin M, Cao Y, Greten FR, Li ZW: NF-κB in cancer: from innocent bystander to major culprit. Nature Rev Cancer. 2002, 2: 301-310.CrossRef
147.
Karin M, Lin A: NF-κB at the crossroads of life and death. Nature Immunol. 2002, 3: 221-227.CrossRef
148.
Bharti AC, Aggarwal BB: Nuclear factor-κB and cancer: its role in prevention and therapy. Biochem Pharmacol. 2002, 64: 883-888.PubMedCrossRef
149.
Arlt A, Vorndamm J, Breitenbroich M, Folsch UR, Kalthoff H, Schmidt WE, Schäfer H: Inhibition of NF-κB sensitizes human pancreatic carcinoma cells to apoptosis induced by etoposide (VP16) or doxorubicin. Oncogene. 2001, 20: 859-868.PubMedCrossRef
150.
Mouria M, Gukovskaya AS, Jung Y, Büchler P, OJ Hines, HA Reber, Pandol SJ: Food-derived polyphenols inhibit pancreatic cancer growth through mitochondrial cytochrome c release and apoptosis. Int J Cancer. 2002, 98: 761-769.PubMedCrossRef
151.
Ron D, Kazanietz MG: New insights into the regulation of protein kinase C and novel phorbol ester receptors. FASEB J. 1999, 13: 1658-1676.PubMed
152.
Trauzold A, Schmiedel S, Sipos B, Wermann H, Westphal S, Roeder C, Klapper W, Arlt A, Lehnert L, Ungefroren H, Johannes F-J, Kalthoff H: Overexpression of PKCμ regulates apoptosis and proliferation in pancreatic tumour cells. Submitted.
153.
van Lint J, Rykx A, Maeda Y, Vantus T, Sturany S, Malhorta V, Vandenheede JR, Seufferlein T: Protein kinase D: an intracellular traffic regulator on the move. Trends Cell Biol. 2002, 12: 193-200.PubMedCrossRef
154.
Johannes F-J, Horn J, Link G, Haas E, Siemienski K, Wajant H, Pfizenmaier K: Protein kinase Cμ dowregulation of tumor-necrosis-factor-induced apoptosis correlates with enhanced expression of nuclear-factor-κB-dependent protective genes. Eur J Biochem. 1998, 257: 47-54.PubMedCrossRef
155.
Datta SR, Brunet A, Greenberg ME: Cellular survival: a play in three Akts. Genes Dev. 1999, 13: 2905-2927.PubMedCrossRef
156.
Burgering BM, Coffer PJ: Protein kinase B (c-Akt) in phosphoinositol-3-OH kinase signal transduction. Nature. 1995, 376: 599-602.PubMedCrossRef
157.
Graff JR, Konicek BW, McNulty AM, Wang Z, Houck K, Allen S, Paul JD, Hbaiu A, Goode RG, Sandusky GE, Vessella RL, Neubauer BL: Increased AKT activity contributes to prostate cancer progression by dramatically accelerating prostate tumor growth and diminishing p27Kip1 expression. J Biol Chem. 2000, 275: 24500-24505.PubMedCrossRef
158.
Jones RG, Parsons M, Bonnard M, Chan VS, Yeh WC, Woodgett JR, Ohashi PS: Protein kinase B regulates T lymphocyte survival, nuclear factor κB activation, and Bcl-X(L) levels in vivo. J Exp Med. 2000, 191: 1721-1734.PubMedCentralPubMedCrossRef
159.
Cheng JQ, Godwin AK, Bellacosa A, Taguchi T, Franke TF, Hamilton TC, Tsichlis PN, Testa JR: AKT2, a putative oncogene encoding a number of a subfamily of protein-serine/threonine kinases, is amplified in human ovarian carcinomas. Proc Natl Acad Sci U S A. 1992, 89: 9267-9271.PubMedCentralPubMedCrossRef
160.
Boehle AS, Kurdow R, Boenicke L, Schniewind B, Faendrich F, Dohrmann P, Kalthoff H: Wortmannin inhibits growth of human non-small-cell lung cancer in vitro and in vivo. Langenbecks Arch Surg. 2002, 387: 234-239.PubMedCrossRef
161.
Podsypanina K, Ellenson LH, Nemes A, Gu J, Tamura M, Yamada KM, Cordon-Cardo C, Catoretti G, Fisher PE, Parsons R: Mutation of Pten/Mmac 1 in mice causes neoplasia in multiple organ systems. Proc Natl Acad Sci U S A. 1999, 96: 1563-1568.PubMedCentralPubMedCrossRef
162.
Suzuki A, de la Pompa JL, Stambolic V, Elia AJ, Sasaki T, del Barco Barrantes I, Ho A, Wakeham A, Itie A, Khoo W, Fukumoto M, Mak TW: High cancer susceptibility and embryonic lethality associated with mutation of the PTEN tumor suppressor gene in mice. Curr Biol. 1998, 8: 1169-1178.PubMedCrossRef
163.
Matsuda K, Idezawa T, You XJ, Kothari NH, Fan H, Korc M: Multiple mitogenic pathways in pancreatic cancer cells are blocked by a truncated epidermal growth factor receptor. Cancer Res. 2002, 62: 5611-5617.PubMed
164.
Gilmore AP, Valentijn AJ, Wang P, Ranger AM, Bundred N, O'Hare MJ, Wakeling A, Korsmeyer SJ, Streuli CH: Activation of BAD by therapeutic inhibition of epidermal growth factor receptor and transactivation by insulin-like growth factor receptor. J Biol Chem. 2002, 277: 27643-27650.PubMedCrossRef
165.
Kermer P, Ankerhold R, Klocker N, Krajewski S, Reed JC, Bahr M: Caspase-9: involvement in secondary death of axotomized rat retinal ganglion cells in vivo. Brain Res Mol Brain Res. 2000, 85: 144-150.PubMedCrossRef
166.
Ng SWS, Tsao M-S, Nicklee T, Hedley DW: Wortmannin inhibits PKB/Akt phosphorylation and promotes gemcitabine antitumor activity in orthotopic human cancer xenografts in immunodeficient mice. Clin Cancer Res. 2001, 7: 3269-3275.PubMed
167.
Ng SSW, Tsao MS, Chow S, Hedley DW: Inhibition of phosphatidylinositide 3-kinase enhances gemcitabine-induced apoptosis in human pancreatic cancer cells. Cancer Res. 2000, 60: 5451-5455.PubMed
168.
Ng SS, Tsao MS, Nicklee T, Hedley DW: Wortmannin inhibits pkb/akt phosphorylation and promotes gemcitabine antitumor activity in orthotopic human pancreatic cancer xenografts in immunodeficient mice. Clin Cancer Res. 2001, 7: 3269-3275.PubMed
169.
Deppert W, Gohler T, Koga H, Kim E: Mutant p53: "gain of function" through perturbation of nuclear structure and function?. J Cell Biochem Suppl. 2000, 35: 115-122.PubMedCrossRef
170.
Moore PS, Sipos B, Orlandini S, Sorio C, Real FX, Lemoine NR, Gress T, Bassi C, Klöppel G, Kalthoff H, Ungefroren H, Lohr M, Scarpa A: Genetic profile of 22 pancreatic carcinoma cell lines. Analysis of K-ras, p53, p16 and DPC4/Smad4. Virchows Arch. 2001, 439: 798-802.PubMedCrossRef
171.
Ghaneh P, Greenhalf W, Humphreys M, Wilson D, Zumstein L, Lemoine NR, Neoptolemos JP: Adenovirus-mediated transfer of p53 and p16 (INK4a) results in pancreatic cancer regression in vitro and in vivo. Gene Ther. 2001, 8: 199-208.PubMedCrossRef
172.
Cascallo M, Calbo J, Gelpi JL, Mazo A: Modulation of drug cytotoxicity by reintroduction of wild-type p53 gene (Ad5CMV-p53) in human pancreatic cancer. Cancer Gene Ther. 2000, 7: 545-556.PubMedCrossRef
Metadata
Title
Apoptosis: Targets in Pancreatic Cancer
Authors
Sabine Westphal
Holger Kalthoff
Publication date
01-12-2003
Publisher
BioMed Central
Published in
Molecular Cancer / Issue 1/2003
Electronic ISSN: 1476-4598
DOI
https://doi.org/10.1186/1476-4598-2-6

Other articles of this Issue 1/2003

Molecular Cancer 1/2003 Go to the issue

Review

Genetic abnormalities in pancreatic cancer

Review

The MUC gene family: Their role in diagnosis and early detection of pancreatic cancer

Research

Expression of peanut agglutinin-binding mucin-type glycoprotein in human esophageal squamous cell carcinoma as a marker

Research

Interfering with TGFβ-induced Smad3 nuclear accumulation differentially affects TGFβ-dependent gene expression

Editorial

Frequently asked questions about Molecular Cancer

Short communication

Regulation of COX-2 transcription in a colon cancer cell line by Pontin52/TIP49a
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits